Doximity, Inc. (DOCS)
| Market Cap | 4.00B -63.6% |
| Revenue (ttm) | 644.86M +13.1% |
| Net Income | 196.05M -12.2% |
| EPS | 0.98 -11.7% |
| Shares Out | 182.87M |
| PE Ratio | 22.31 |
| Forward PE | 15.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,621,463 |
| Open | 21.74 |
| Previous Close | 21.59 |
| Day's Range | 21.59 - 22.30 |
| 52-Week Range | 17.15 - 76.51 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 24.37 (+11.48%) |
| Earnings Date | Aug 6, 2026 |
About DOCS
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for DOCS stock is "Buy." The 12-month stock price target is $24.37, which is an increase of 11.48% from the latest price.
News
Did Doximity Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Doximity downgraded to Underperform from Buy at BofA
BofA analyst Allen Lutz downgraded Doximity (DOCS) to Underperform from Buy with a price target of $20, down from $38, citing limited clarity on the near-term trajectory of revenue and…
Doximity price target lowered to $26 from $28 at JPMorgan
JPMorgan lowered the firm’s price target on Doximity (DOCS) to $26 from $28 and keeps a Neutral rating on the shares. The firm adjusted targets in the health technology space…
Doximity management to meet virtually with Piper Sandler
Virtual Meeting to be held on June 17 hosted by Piper Sandler.
Doximity to Present at the William Blair 46th Annual Growth Stock Conference
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the Wil...
Cisco upgraded, Doximity downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Doximity downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Doximity (DOCS) to Equal Weight from Overweight with a $20 price target
Barclays downgrades Doximity on slowing industry growth
Barclays downgraded Doximity (DOCS) to Equal Weight from Overweight with a price target of $20, down from $38. Growth in the digital advertising space is slowing while competition is ramping,…
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?
Doximity ($DOCS) shares fell 24% after the company posted mixed Q4 results and issued a weaker outlook for FY2027, which led several analysts to cut their ratings. The sell-off reflects…
Doximity price target lowered to $19 from $29 at Truist
Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $19 from $29 and keeps a Hold rating on the shares after the company’s Q1 results and…
Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending
Shares of Doximity (NYSE: DOCS) plunged on Thursday after the telehealth platform reported weaker-than-expected quarterly profit and issued fiscal 2027 revenue guidance that fell significantly short o...
Doximity Earnings Call Transcript: Q4 2026
Q4 and full-year results exceeded guidance, with strong free cash flow and accelerating AI engagement. FY27 guidance reflects modest revenue growth and continued AI investment, with minimal near-term AI revenue but strong long-term potential.
Doximity Earnings release: Q4 2026
Doximity released its Q4 2026 earnings on May 13, 2026, summarizing the period's financial results.
Doximity Annual report: Q4 2026
Doximity has published its Q4 2026 annual report on May 13, 2026.
Doximity Partners with Aledade to Bring Clinical AI to Value-Based Care Settings
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced an integration with Aledade, a physician‑led, national leader ...
Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 fourth quarter and fiscal year ende...
Doximity Slides: Investor presentation
Doximity has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter ...
Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report examining how physicians are adopting artificial i...
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
Doximity Earnings Call Transcript: Q3 2026
Q3 revenue grew 10% year-over-year to $185.1M, with a 60% adjusted EBITDA margin and strong engagement across workflow and AI products. Delayed pharma budgets and policy headwinds impacted Q4 outlook, but double-digit growth is expected by year-end as AI commercialization ramps.
Doximity Quarterly report: Q3 2026
Doximity has published its Q3 2026 quarterly earnings report on February 5, 2026.